Ricerca Immagini Maps Play YouTube News Gmail Drive Altro »
Accedi
Gli utenti che utilizzano screen reader possono fare clic su questo link per attivare la modalità di accessibilità. Questa modalità presenta le stesse funzioni principali, ma risulta maggiormente compatibile con il reader.

Brevetti

  1. Ricerca brevetti avanzata
Numero di pubblicazioneWO1990013641 A1
Tipo di pubblicazioneRichiesta
Numero domandaPCT/US1990/002656
Data di pubblicazione11 nov 1990
Data di registrazione10 mag 1990
Data di priorità10 mag 1989
Pubblicato anche comeCA2055435A1, EP0471796A1, EP0471796A4
Numero di pubblicazionePCT/1990/2656, PCT/US/1990/002656, PCT/US/1990/02656, PCT/US/90/002656, PCT/US/90/02656, PCT/US1990/002656, PCT/US1990/02656, PCT/US1990002656, PCT/US199002656, PCT/US90/002656, PCT/US90/02656, PCT/US90002656, PCT/US9002656, WO 1990/013641 A1, WO 1990013641 A1, WO 1990013641A1, WO 9013641 A1, WO 9013641A1, WO-A1-1990013641, WO-A1-9013641, WO1990/013641A1, WO1990013641 A1, WO1990013641A1, WO9013641 A1, WO9013641A1
InventoriEli Gilboa, Bruce Sullenger
CandidatoSloan Kettering Inst Cancer
Esporta citazioneBiBTeX, EndNote, RefMan
Link esterni:  Patentscope, Espacenet
Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
WO 1990013641 A1
Estratto
Une cellule eucaryote transformée de manière stable comprend un promoteur pol III et un ADN étranger susceptible d'être transcrit sous la direction du promoteur pol III. Un vecteur rétroviral comprend un ARN-t chimérique introduit dans la séquence répétitive teerminale longue en 3' du vecteur rétroviral.
Descrizione  disponibile in inglese
Rivendicazioni  disponibile in inglese
Citazioni di brevetti
Brevetto citato Data di registrazione Data di pubblicazione Candidato Titolo
US4497796 *8 dic 19825 feb 1985The Regents Of The University Of CaliforniaGene transfer in intact mammals
Citazioni diverse da brevetti
Riferimento
1 *Cell, Volume 43, published December 1985. J. TOBIAN, et al. "tRNA nuclear transport: defining the critical regions of human tRNA (i)(met) by point mutagenesis" pp. 415-422. see entire article.
2 *CHEMICAL ABSTRACTS, Volume 111, No. 13, issued 1989, September 25 (Columbus, Ohio, U.S.A.), E. GILBOA, et al. "Retroviral gene transfer: applications to human therapy" see page 110247, column 1, the Abstract No. 110249f, Adv. Exp. Biol. Med. 1988, 241 (Mol. Biol. Hemopoesis), 29-33 (Eng).
3 *Cold Spring Harbor Sym. on Mol. Biol., Volume LI. published 1986. A. MILLER, et al. "Transfer of genes into human somatic cells using retrovirus vectors" pp. 1013-1019. see entire article.
4 *EMBO J., Volume 6, Number 10, published October 1987. P. JENNINGS, et al. "Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III" pp. 3043-3047. see entire article.
5 *EMBO J., Volume 6, Number 2, published February 1987. N. TAKAMATSU, et al. "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA" pp. 307-311. see entire article.
6 *J. Virol., Volume 63, Number 2, published February 1989. T. VON RUDEN, et al. "Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA" pp. 677-682. see entire article.
7 *J. Virol., Volume 63, Number 3, published March 1989. M. HADZOPOULOU-CLADARAS, et al. "The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region" pp. 1265-1274 see entire article.
8 *Nature, Volume 323, published 25 September 1986. J. ZARLING, et al. "T-cell responses to human AIDS virus in macaques immunized with recombinant virus" pp. 344-346. see entire article.
9 *Nature, Volume 335, published 29 September 1988. A. FRIEDMAN, et al. "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus" pp. 452-454. see entire article.
10 *Nature, Volume 335, published 29 September 1988. D. BALTIMORE "Intracellular Immunization" pp. 395-396. see entire article.
11 *Nucl. Acid. Res., Volume 11, Number 6, published 1983. D.JOLLY, et al. "Elements in the long terminal repeat of murine retroviruses stable transformation by thymidine kinase gene", pp. 1855-1872. see entire document.
12 *Nucl. Acid. Res., Volume 12, Number 2, published 1984. S. ADENIYI-JONES, et al. "Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNA (i)(met) gene" pp. 1101-1115. see entire article.
13 *See also references of EP0471796A1
Con riferimenti in
Brevetto con rif. Data di registrazione Data di pubblicazione Candidato Titolo
WO1994026877A1 *17 mag 199424 nov 1994Univ CaliforniaTherapie genique ribozymique contre l'infection par le vih et contre le sida
WO1995021912A1 *14 feb 199517 ago 1995Australian Red CrossSouches non pathogenes de vih-1
WO1995027783A1 *5 apr 199519 ott 1995Joshi Sukhwal SadnaInhibition de la multiplication du vih-1 dans des cellules de mammiferes
WO2001029070A218 ott 200026 apr 2001Genentech IncRecepteur tccr de cytokine de type i
WO2007038658A226 set 20065 apr 2007Medarex IncConjugues anticorps-medicament et leurs methodes d'utilisation
WO2009102488A213 feb 200920 ago 2009Univ TuftsModèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire
DE4225094A1 *29 lug 19924 nov 1993Frank Andreas Harald MeyerMedikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
EP0596901A1 *27 mag 199218 mag 1994City Of HopeMOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt?LYS
EP0971033A221 gen 199212 gen 2000IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINEEssai et modèle pour la maladie d'Alzheimer
EP1666591A125 giu 19967 giu 2006Immunex CorporationCytokine induisant l'apoptose
EP1757618A222 mar 200128 feb 2007Curagen CorporationProteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines
EP1772515A112 mag 200011 apr 2007Immunex CorporationImmunorégulateur de la famille nommée 'récepteurs semblables à des récepteurs de leucocytes de type immunoglobuline' (LIR)
EP1865061A214 mag 199912 dic 2007Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1944317A229 ago 200116 lug 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1953173A122 mag 20006 ago 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1956030A122 mag 200013 ago 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1995321A218 lug 200626 nov 2008Genentech, Inc.Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2002714A116 nov 200617 dic 2008Genentech, Inc.Nouvelles ruptures génétiques, compositions et procédés associés à celles-ci
EP2050335A19 feb 200722 apr 2009Genentech, Inc.Dislocation de gènes, compositions et procédés correspondants
EP2075334A122 giu 20011 lug 2009Genentech, Inc.Acides nucléiques EG-VEGF et polypeptides et procédés d'utilisation
EP2082645A118 apr 200729 lug 2009Genentech, Inc.Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2110434A124 feb 200321 ott 2009Genentech, Inc.Recepteur de cytokine de type 1 GLM-R
EP2163625A120 dic 200017 mar 2010Genentech, Inc.Polypeptides homologues IL-17 et IL-17R et utilisations thérapeutiques
EP2186402A118 mag 200619 mag 2010Genentech, Inc.Modèles d'animaux knock-out et leur utilisation
EP2228446A11 dic 200015 set 2010Genentech, Inc.Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci
EP2258848A120 dic 20008 dic 2010Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP2266986A131 mag 200229 dic 2010Medarex, Inc.Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci
EP2277908A22 giu 200426 gen 2011Genentech, Inc.Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées
EP2290081A220 dic 20002 mar 2011Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP2333069A214 mag 199915 giu 2011Genentech, Inc.Utilisations thérapeutiques de polypeptides homologues de IL-17
EP2354163A226 set 200610 ago 2011Medarex, Inc.Conjugué d'un anticorps anti-cd4 ou anti-psma et duocarmycine
EP2450050A120 nov 20079 mag 2012Genentech, Inc.Polypeptides hétérologues IL-14A/F et utilisations thérapeutiques associées
US5583035 *14 nov 199410 dic 1996Bayer AktiengesellschaftHIV antisense expression vectors
US5631360 *5 mag 199520 mag 1997Ribozyme Pharmaceuticals, Inc.N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites
US5670361 *17 mag 199423 set 1997The Regents Of The University Of CaliforniaInsertion retrovirus into nucleic acid
US5686599 *2 mag 199511 nov 1997Ribozyme Pharmaceuticals, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683 *5 mag 19958 set 1998Ribozyme Pharmaceuticals, Inc.Reacting with an alkylamine or ammonium hydroxide/alkylamine mixture at 60-70 degrees c. for 5 to 15 minutes in order to remove any exocyclic protecting groups
US5831071 *29 ago 19973 nov 1998Ribozyme Pharmaceuticals, Inc.Synthesis deprotection analysis and purification of RNA and ribozymes
US5854038 *14 ott 199429 dic 1998University Research CorporationLocalization of a therapeutic agent in a cell in vitro
US5871958 *3 nov 199416 feb 1999Duke UniversityViricides; genetic engineering
US5902880 *10 nov 199411 mag 1999Ribozyme Pharmaceuticals, Inc.Non-naturally occuring rna having ribonucleotides at 3' and 5' terminals which hydrogen bond; increases stability; increases level of production of exogenous rna; for gene therapy
US5955644 *8 ago 199621 set 1999M.D. Anderson Cancer CenterMutants, mice
US6015661 *7 giu 199518 gen 2000The Macfarlane Burnet Centre For Medical Research LimitedMethods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
US6057489 *12 set 19962 mag 2000M.D. Anderson Cancer CenterMouse cell heterozygous for mutation in recombinational repair pathway; used in screening for proteins that rescue the senescence phenotype in mmrad51/p53-deficient cells
US6132962 *16 giu 199717 ott 2000The Regents Of The University Of CaliforniaRetroviral vectors comprising an anti-hiv or other nucleic acid
US6146886 *7 ago 199514 nov 2000Ribozyme Pharmaceuticals, Inc.Transcribed non-naturally occurring rna having a stabilizing intramolecular stem formed by base-pairing interactions between 3' region and 5' complementary nucleotides; antisense agents; decoys; ribozymes; agonist/antagonist rna
US6162898 *21 ago 199819 dic 2000Duke UniversityProtein having one or more mutations from amino acid position 68 to 90 and which suppresses the phenotypic expression of the wild-type rev gene of human immunodeficiency virus-1; viricides
US62516752 giu 199526 giu 2001Duke UniversityMethods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US628780930 dic 199811 set 2001Novartis AgProtein which represses phenotypic expression of wild-type rex gene of human t-cell leukemia/lymphoma virus-1 or -2 and/or wild-type rev gene of human immunodeficiency virus-1; viricides; prophylaxis
US633915021 ago 199815 gen 2002Duke UniversityA genetically mutated viricide gene; therapy for lymphadenopathy associated virus
US635309817 giu 19985 mar 2002Ribozyme Pharmaceuticals, Inc.Deprotecting and purifying rna
US643711727 lug 199920 ago 2002Ribozyme Pharmaceuticals, Inc.Anion exchange high-performance liquid chromatography; elution, recovering
US64691582 mag 199522 ott 2002Ribozyme Pharmaceuticals, IncorporatedLoading a mixture of rna on to an anion exchange high-performance liquid chromatography (hplc) column, eluting with buffer and collecting eluate; purifying in enzymatically active form
US664975128 mag 200218 nov 2003Sirna Therapeutics, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US667017719 giu 199830 dic 2003Advanced Research And Technology Institute, Inc.Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus
US67769866 giu 199717 ago 2004Novartis AgInhibition of HIV-1 replication by antisense RNA expression
US68525352 ago 20008 feb 2005Sirna Therapeutics, Inc.Polymerase III-based expression of therapeutic RNAS
US704181730 ago 20029 mag 2006Sirna Therapeutics, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US708397913 set 19991 ago 2006Indiana University FoundationMethods for enhanced retroviral-mediated gene transfer
US717311511 gen 20016 feb 2007Genentech, Inc.Stra6 polypeptides
US723563313 nov 200226 giu 2007Genentech, Inc.Comprises membrane protein for use in the diagnosis, prevention and treatment of tumor disorders
US765937525 giu 20079 feb 2010Immunex CorporationHuman IL-1 epsilon DNA and polypeptides
US77051954 giu 200327 apr 2010Genentech, Inc.Screening method
US774143922 mag 200622 giu 2010Genentech, Inc.For stimulating release of tumor necrosis factor and/or cellular prolifefration/differentiation of chondrocytes by contacting blood w/polypeptide; diagnosis cancer
US775946715 giu 200620 lug 2010Indiana University Research And Technology CorporationEnhanced mediated DNA transfer
US785527831 ott 200721 dic 2010Genentech, Inc.Antibodies to Stra6 polypeptides
US793965018 lug 200610 mag 2011Genentech, Inc.Stra6 polypeptides
US832418213 feb 20094 dic 2012Tufts UniversityHumanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US853591215 ott 201017 set 2013Genentech, Inc.Chimeric fibroblast growth factors with altered receptor specificity
Classificazioni
Classificazione internazionaleA61K39/21, A01K67/027, A61P37/04, C12N15/82, A01H5/00, C12N15/09, C12N15/79, C12N15/85, C12N5/10, C12P21/00, C12N15/67, A61K38/00, A61P31/12, A61K31/70, C12R1/91, C12N15/11, C12N15/113
Classificazione cooperativaC12N15/85, A01K67/027, C12N15/67, C12N15/1132, C12N15/8218, C12N15/79, C12N15/11, C12N2310/13
Classificazione EuropeaC12N15/67, C12N15/85, C12N15/79, C12N15/82B4, C12N15/11, A01K67/027, C12N15/113A1
Eventi legali
DataCodiceEventoDescrizione
30 lug 1998WWW
Ref document number: 1990909233
Country of ref document: EP
26 feb 1992WWP
Ref document number: 1990909233
Country of ref document: EP
10 dic 1991WWE
Ref document number: 1990909233
Country of ref document: EP
7 nov 1991WWE
Ref document number: 2055435
Country of ref document: CA
7 nov 1991ENP
Ref country code: CA
Ref document number: 2055435
Kind code of ref document: A
Format of ref document f/p: F
15 nov 1990AK
Kind code of ref document: A1
Designated state(s): CA JP US
15 nov 1990AL
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE